title: Advances in Intra-abdominal Sepsis: What Is New?
abstract: We have reviewed the literature regarding recent advances in the management of intra-abdominal sepsis, with a focus on antimicrobial agents, duration of therapy, and source control. Several important developments in these areas are discussed in this review. The introduction of a new antimicrobial agent-ceftolozane/tazobactam-marks the first novel agent for treating intra-abdominal infections in a number of years, and its indications for use and supporting evidence are reviewed here. In addition, we discuss recent evidence that clarifies the importance of early source control for intra-abdominal infection and new data that suggests that an abbreviated course of antimicrobial therapy for intra-abdominal infection is equally effective as prolonged therapy.
authors.affiliation: Department of Surgery, The University of Virginia Health System, Charlottesville, VA, USA.
authors.forename: Zachary C
authors.initials: ZC
authors.lastname: Dietch
authors.forename: Puja M
authors.initials: PM
authors.lastname: Shah
authors.forename: Robert G
authors.initials: RG
authors.lastname: Sawyer